CARLSBAD, Calif.--(BUSINESS WIRE)--Arima Genomics, Inc., a company leveraging 3D genomics to reveal actionable insights that will empower researchers and clinicians to improve human health, today ...

Appointment strengthens leadership team to drive strategy focused on harnessing 3D multi-omics to identify high-confidence, high-value therapeutic targets, to accelerate drug discovery CAMBRIDGE, ...

Fox Chase Cancer Center and Arima Genomics Partner to Advance 3D Genome Diagnostics for Cancer Care The partnership enables Fox Chase to become the first NCI-designated Comprehensive Cancer Center to ...

Enhanc3D Genomics (‘Enhanced’), an innovator in 3D genomics technology, today announced the launch of a suite of integrated multi-omics solutions to accelerate and improve the precision of drug ...

The biggest challenge in drug development is that the process is not an even balance of hit or miss – it is overwhelmingly miss, with around 90% of drugs never making it beyond clinical trials. As a ...

For patients with challenging cancers like lymphoma and sarcoma, subtle genetic differences can dramatically change the way doctors diagnose and treat their disease. There are more than 70 recognized ...

Enhanced Genomics ('Enhanced'), the biotechnology company pioneering 3D multi-omics to rapidly identify high-confidence, genetically validated drug targets for common diseases, today announced it has ...

In particular, genome-wide association studies (GWAS) have pinpointed hundreds of genes associated with disease risk, enabling the development of drugs targeting a broad range of highly prevalent ...

PHILADELPHIA, PA & CARLSBAD, CA — Fox Chase Cancer Center and Arima Genomics, Inc. have launched a first-of-its-kind partnership aimed at bringing advanced cancer diagnostics based on the ...

The partnership enables Fox Chase to become the first NCI-designated Comprehensive Cancer Center to implement clinical testing utilizing Arima's 3D-genomics technology in multiple tumor types as part ...